C3H/HeJ |
Increased |
High cortical; normal trabecular [low vertebral] (60) |
C57BL/6J |
Reduced |
Normal |
Rosiglitazone treatment |
Increased |
Low in some strains of mice tested (60, 62) |
11 β OHase null (−/−) |
None |
Normal |
Ebf1 null (−/−) |
Increased |
High early then subsequently low (32) |
Glucocorticoid treatment |
Increased or unchanged |
Low (99) |
Wnt10b overexpression in bone (osteocalcin promoter) |
Reduced |
High (100) |
Small (Irs1 mutant) |
None |
Low (76) |
Little (ghrh-deficient) |
Increased |
Low (80) |
LID (targeted Igf-I liver-deficient) |
Normal |
Low (80) |
Calorie restriction, C57BL/6 mice- young |
Increased |
Low (14, 15) |
High-fat diet, C57BL/6 |
Normal to increased |
Normal to slightly low (15) |
Ob/Ob (leptin deficient) |
Increased |
Low in femur; high in vertebrae (70) |
C57BL/6 ovariectomy |
Increased |
Low (80) |
Igfbp2 null −/− |
Increased |
Low (101) |
Lactation at day 7, C57BL/6 |
Reduced |
Low (C.J.R., unpublished observation) |
aP2-FoxC2 Tg, overexpression of FoxC2 in adipose cells |
Increased |
Increased (Beata Lecka-Czernik, PhD, unpublished observation) |
Insulin deficiency, diabetes mellitus C57BL/6 |
Increased |
Decreased (57) |
Insulin resistance, C57BL/6 |
Normal to increased |
Normal to slightly low (15) |
Lrp5, High bone mass gene Tg (overexpression) |
Reduced |
Increased (102) |
Lrp5-deficient mice |
Increased |
Decreased (103) |
BADGE treatment (PPARγ antagonist) |
Decreased |
Unchanged or increased (104) |
Radiation (therapeutic or ablative) |
Increased |
Reduced (105) |
A-Zip |
Reduce |
High |